Johnson & Johnson Reports Strong Growth in Cardiovascular Devices, Raises Financial Outlook

Johnson & Johnson (J&J) has announced robust growth in its cardiovascular device sales, leading to an upward revision of its financial projections for 2025. The company's MedTech division, particularly its cardiac device segment, has shown significant progress despite earlier challenges in its pulsed field ablation market entry.

Cardiovascular Division Leads Growth

J&J's cardiovascular division reported a remarkable 23.5% year-over-year growth in the second quarter of 2025, reaching $2.31 billion in sales. The electrophysiology segment contributed significantly, with an 11% gain and revenues of $1.47 billion, split evenly between domestic and international markets.

The Abiomed unit, specializing in miniaturized heart pumps, saw an 18.2% increase in sales, totaling $448 million. Additionally, Shockwave Medical, acquired by J&J, added $292 million in revenue with its intravascular lithotripsy catheters.

Varipulse System Update and Market Position

After a brief pause in January due to safety concerns, J&J's Varipulse pulsed field ablation system has regained momentum. Tim Schmid, J&J MedTech's worldwide chairman, emphasized the company's commitment to the electrophysiology market, stating, "We are not rolling over."

The FDA recently granted an updated approval for a new irrigation flow rate for the Varipulse system, based on real-world data. J&J reports that over 10,000 Varipulse procedures have been performed worldwide, with a neurovascular complication rate of less than 0.5%.

Overall Performance and Future Outlook

J&J MedTech's total sales reached $8.54 billion, representing a 7.3% growth for the quarter. The company as a whole, including its pharmaceutical division, reported $23.7 billion in total sales, a 5.8% increase.

CEO Joaquin Duato expressed optimism about the company's future, citing anticipated approvals and submissions in various therapeutic areas. J&J has increased its full-year sales estimate midpoint by $2 billion to 5.4%, resulting in a more than 5.5% jump in stock price to approximately $164.

While tariff-related uncertainties persist, J&J expects the impact to be less severe than initially projected, potentially reducing from $400 million to half that amount for the year.